Stay updated on Surufatinib, Toripalimab & Chemo in 2nd-line CRC Clinical Trial
Sign up to get notified when there's something new on the Surufatinib, Toripalimab & Chemo in 2nd-line CRC Clinical Trial page.

Latest updates to the Surufatinib, Toripalimab & Chemo in 2nd-line CRC Clinical Trial page
- ChecktodayChange DetectedThe page now displays a 403 Forbidden error instead of the study record, indicating restricted access to the study details.SummaryDifference18%

- Check8 days agoNo Change Detected
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedRevision tag updated from v3.6.5 to v3.6.6, indicating a new version of the page.SummaryDifference0.1%

- Check43 days agoChange DetectedA new revision tag indicates the system was updated from v3.6.4 to v3.6.5. This reflects an incremental platform update rather than changes to page content.SummaryDifference0.1%

- Check50 days agoChange DetectedThe page content remained unchanged. There are no additions or deletions to report.SummaryDifference0.1%

- Check57 days agoChange DetectedThe page’s revision label advanced from v3.6.3 to v3.6.4, indicating an internal deployment or version update. This update does not reflect changes to the study content displayed on the page.SummaryDifference0.1%

- Check79 days agoChange DetectedThe Study Details page revision tag updates from v3.6.2 to v3.6.3, indicating a small platform update to the page.SummaryDifference0.1%

Stay in the know with updates to Surufatinib, Toripalimab & Chemo in 2nd-line CRC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Surufatinib, Toripalimab & Chemo in 2nd-line CRC Clinical Trial page.